Bastion Asset Management Inc. Purchases New Stake in Progyny, Inc. (NASDAQ:PGNY)

Bastion Asset Management Inc. purchased a new position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,044 shares of the company's stock, valued at approximately $850,000. Bastion Asset Management Inc. owned approximately 0.06% of Progyny at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Voya Investment Management LLC grew its stake in shares of Progyny by 1.4% during the fourth quarter. Voya Investment Management LLC now owns 51,792 shares of the company's stock worth $893,000 after buying an additional 701 shares during the last quarter. GAMMA Investing LLC increased its holdings in Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after purchasing an additional 1,246 shares in the last quarter. Signaturefd LLC boosted its stake in shares of Progyny by 1,355.0% during the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after purchasing an additional 1,355 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after purchasing an additional 1,526 shares during the last quarter. Finally, KBC Group NV increased its stake in shares of Progyny by 84.6% in the fourth quarter. KBC Group NV now owns 4,669 shares of the company's stock valued at $81,000 after buying an additional 2,140 shares during the period. Institutional investors own 94.93% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on PGNY. BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target for the company in a research report on Monday, March 31st. Bank of America increased their price target on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Canaccord Genuity Group lifted their price objective on Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research note on Friday, February 28th. Finally, JPMorgan Chase & Co. increased their target price on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Eight research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $23.64.

Progyny Stock Down 0.2 %

NASDAQ:PGNY traded down $0.04 during trading hours on Tuesday, reaching $23.36. The company had a trading volume of 1,041,981 shares, compared to its average volume of 1,745,644. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of 40.28, a P/E/G ratio of 2.39 and a beta of 1.37. The business's 50-day simple moving average is $21.91 and its two-hundred day simple moving average is $19.40. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $33.84.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.